Jasper Therapeutics, Inc. JSPR
0.61
0.02
3.39%
as of 25 Sep
- Market cap
- $19.5M
- P/E
- 0.0×
Follow JSPR
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Current Ratio |
1.48 | 2.26 | 2.62 | 2.59 |
+8 more quarters Free account |
Net Debt/EBITDA |
0.84 | 1.29 | 1.85 | 2.69 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
2.51 | 12.39 | 2.40 | 0.91 | |
Capex/Depreciation |
3.81 | 0.00 | 0.00 | 0.00 | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(0.24) | (0.51) | (1.14) | (1.02) | |
Cash per Share |
0.27 | 0.49 | 1.50 | 3.06 | |
Shareholders Equity per Share |
0.05 | 0.12 | 0.22 | 0.70 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.05 | 0.12 | 0.22 | 0.70 | |
Free Cash Flow |
(6.84) | (14.55) | (21.87) | (17.00) | |
Working Capital |
3.73 | 11.30 | 21.45 | 33.52 | |
Capital Expenditures |
0.08 | — | 0.00 | 0.00 | |
Net Current Asset Value |
1.18 | 2.51 | 3.02 | 8.67 | |
| Other line items | |||||
Quick Ratio |
0.99 | 1.57 | 2.17 | 2.42 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.24) | (0.51) | (1.14) | (1.02) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Payables |
5.41 | 2.72 | 5.12 | 6.13 | |
Average Assets |
29.13 | 39.39 | 57.84 | 78.44 | |
Average Common Equity |
12.46 | 22.82 | 32.91 | 47.63 | |
Capex to Sales |
0.00 | — | 0.00 | 0.00 | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates